Recursion Pharmaceuticals Inc (RXRX)
6.40
+0.08
(+1.27%)
USD |
NASDAQ |
Nov 01, 16:00
6.405
0.00 (0.00%)
After-Hours: 20:00
Recursion Pharmaceuticals Revenue (Quarterly): 14.40M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 14.40M |
March 31, 2024 | 13.49M |
December 31, 2023 | 10.62M |
September 30, 2023 | 10.10M |
June 30, 2023 | 11.02M |
March 31, 2023 | 12.13M |
December 31, 2022 | 13.68M |
September 30, 2022 | 13.05M |
Date | Value |
---|---|
June 30, 2022 | 7.653M |
March 31, 2022 | 5.299M |
December 31, 2021 | 2.50M |
September 30, 2021 | 2.50M |
June 30, 2021 | 2.50M |
March 31, 2021 | 2.50M |
December 31, 2020 | 2.551M |
September 30, 2020 | 0.862M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.862M
Minimum
Sep 2020
14.40M
Maximum
Jun 2024
7.804M
Average
8.878M
Median
Revenue (Quarterly) Benchmarks
Eli Lilly and Co | 11.44B |
Pfizer Inc | 17.70B |
Revance Therapeutics Inc | 65.39M |
Twist Bioscience Corp | 81.46M |
NovaBay Pharmaceuticals Inc | 2.40M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -97.54M |
Total Expenses (Quarterly) | 114.95M |
EPS Diluted (Quarterly) | -0.40 |
Enterprise Value | 1.363B |
Gross Profit Margin (Quarterly) | 36.14% |
Profit Margin (Quarterly) | -677.2% |
Earnings Yield | -25.62% |
Normalized Earnings Yield | -25.62 |